- Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385-94.
- Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. [AASLD Practice Guidelines].
- Fede G, D'Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012 Apr. 56(4):810-8.
- Casado, M, Bosch, J, and García-Pagán JC. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114(6):1296-1303.
- Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Annals of Hepatology. 2002;1(2):72-79.
- Gentilini P, Vizzutti F, Gentilini A, et al. Update on ascites and hepatorenal syndrome. Digestive and Liver Disease. 2002;34(8):592-605.
- Fukui H. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol. 2015; 21(41):11584 11596.
- Moore KP, Wong F, Gines P, et al.The management of ascites in cirrhosis: Report on the consensus conference the International Ascites Club. Hepatology. 2003;38(1):258-266.
- Sola E, Sole C and Gines P. Management of uninfected and infected ascites in cirrhosis. Liver Int. 2016;36 Suppl 1:109–115.
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis Journal of Hepatology 2018 vol. 69 j 406–460.
- Runyon BA and Aasld. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651–1653.
- Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonacademic cirrhosis. A randomized comparative study of efficacy and safety. Journal of Hepatology. 2003;39(2):187-192.
- Pache I and Bilodeau M. Severe hemorrhage following abdominal paracentesis for ascites in patients with liver disease. Alimentary Pharmacology & Therapeutics. 2005;21(5):525-529.
- Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis. 2011;43(11):881–886.
- Rossel M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. New England Journal of Medicine. 2000;342(23):1701-1707
- Deltenre P, Mathurin P, Dharancy S, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005; 25: 349–356.
- Rossel M. TIPS: 25 years later. Journal of Hepatology. 2013;59(5):1081-1093.
- La Mura V and Salerno F. Therapy of the refractory ascites: Total paracentesis vs. TIPS. Gastroenterología y Hepatología 2015;39(7):477-480.
- Saab S, Nieto JM, Lewis SK, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. The Cochrane Database of Systematic Reviews. 2006;(4):CD004889 .
- Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: A meta‐analysis of individual patient data. Gastroenterology. 2007;133(3):825-834.
- Boyer TD and Haskal ZJ, D. American Association for the Study of Liver. The role of a transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41(2):386-400.
- Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016; 7: 629–650.
- Inoue N, Yamazaki Z, Oda T, et al. Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Transactions - American Society for Artificial Internal Organs 1977; 23: 699–702.
- Zaak D, Paquet KJ and Kuhn R. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol. 2001;39(1):5–10.
- Bellot P, Welker MW, Soriano G, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol 2013;58:922–927.
- Stirnimann G, Berg T, Spahr L, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther 2017;46:981–991.
- Bureau C, Adebayo D, Chalret de Rieu M, et al. Alfapump_ system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol 2017;67:940–949.
- Sola E, Sanchez-Cabus S, Rodriguez E, et al. Effects of alfapump system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transpl 2017;23:583–593.
- Hariprasad MK, Paul PK, Eisinger RB, et al. Extracorporeal dialysis of ascites. A new technique. Arch Intern Med 1981; 141: 1550–1551.
- Raju SF and Achord JL. The effects of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites. Am J Gastroenterol 1984; 79: 308–312.
- Brett Fortune and Andres Cardenas. Ascites, refractory ascites, and hyponatremia in cirrhosis. Gastroenterology Report 2017;5(2): 104–112
|
